STD RECENT EXPOSURE

SKU 4001
$349.00
In stock
1
Product Details

Why Take This Test?

Recent exposure and you want to know now without waiting 6 or more weeks. We perform 9 tests to evaluate for recent exposure to sexually transmitted diseases. In the event some of these tests are positive the laboratory will automatically perform additional testing as required to assist your doctor with an accurate diagnosis and or confirmation so that you can make informed treatment decisions with your healthcare provider. These additional tests, if needed will be billed to the credit card used to purchase this panel. You will receive a courtesy call to let you know these charges are being processed.

Includes:

1. CHLAMYDIA/GC RNA, TMA,

Includes

Chlamydia trachomatis, Neisseria gonorrhoeae

Methodology

Dual Kinetic Assay (DKA) • Target Capture • Transcription-Mediated Amplification (TMA)

This test was performed using the APTIMA® COMBO2 Assay (GEN-PROBE).

Clinical Significance

C. trachomatis infections are the leading cause of sexually transmitted diseases in the United States. C. trachomatis is known to cause cervicitis, pelvic inflammatory disease (PID), epididymitis and proctitis. It is also the most frequent cause of non-gonococcal urethritis in men. Among women, the consequences of Chlamydialinfections are severe if left untreated.

Approximately half of Chlamydial infections are asymptomatic.
Neisseria gonorrhoeae (gonococci) is the causative agent of gonorrhea. In men, this disease generally results in anterior urethritis accompanied by purulent exudate. In women, the disease is most often found in the cervix, but the vagina and uterus may also be infected.

2. Hep A AB, Total

Methodology

Immunoassay (IA)

Reference Range(s)

Non-Reactive

Clinical Significance

HAV antibody indicates prior or acute infection with, or immunization to, Hepatitis A virus.

Alternative Name(s)

HAV Total,HAV Antibody

3. Hep B CORE AB TOTAL

Methodology

Immunoassay (IA)

Limitations

Patients receiving mouse antibody therapy may produce false-negative results. False-positives may be detected shortly after immunization to influenza and with patients with hypergammalobulinemia, positive rheumatoid factor, and connective tissue disorders.

Reference Range(s)

Non-Reactive

Clinical Significance

This assay does not distinguish between Total B core antibody IgG and IgM detected before or at the onset of symptoms; however, such reactivity can persist for years after illness, and may even outlast anti-HBs. Occasionally Hepatitis B core antibody may be the only marker of either current or past Hepatitis B infection.

4. Hep C AB

Includes

If Hepatitis C Antibody is reactive, then Hepatitis C Viral RNA, Quantitative, Real-Time PCR will be performed at an additional charge (CPT code(s): 87522).

Limitations

Results obtained from immunosuppressed patients should be interpreted with caution. Patients receiving mouse antibody therapy may produce false-negative results.

Clinical Significance

Hepatitis C Virus (HCV) is a major cause of hepatitis. The clinical symptoms of an HCV infection are variable. Infection with HCV results in a chronic infection in 50 to 80% of cases. The "window" between HCV acquisition and seroreactivity is highly variable; up to six months.

Alternative Name(s)

HCV with Reflex,HCV Antibody,Anti HCV

5. HSV 1/2 IGG HERPSELECT W REF

Includes

If Herpes Simplex Virus 2 (IgG) is >1.09, then HSV-2 Inhibition Study will be performed at an additional charge (CPT code(s): 86696).

Methodology

Immunoassay (IA)

Reference Range(s)

Index Interpretation
<0.90 Negative
0.90-1.09 Equivocal
>1.09 Positive
This assay utilizes recombinant type-specific antigens to differentiate HSV-1 from HSV-2 infections. A index positive result cannot distinguish between recent and past infection. If recent HSV infection is suspected but the results are negative or equivocal, the assay should be repeated in 4-6 weeks. The performance index characteristics of the assay have not been established for pediatric populations, immunocompromised patients, or neonatal screening.


Clinical Significance

Herpes Simplex Virus (HSV) is responsible for several clinically significant human viral diseases, with severity ranging from inapparent to fatal. Clinical manifestations include genital tract infections, neonatal herpes, meningoencephalitis, keratoconjunctivitis, and gingivostomatitis. There are two HSV serotypes that are closely related antigenically. HSV type 2 is more commonly associated with genital tract and neonatal infections, while HSV type 1 is more commonly associated with infections of non-genital sites. Specific typing is not usually required for diagnosis or treatment. The mean time to seroconversion using the type specific assay is 25 days. The performance of this assay has not been established for use in a pediatric population, for neonatal screening, or for testing of immunocompromised patients.

6. SYPHILIS

Includes

If RPR Screen is reactive, RPR titer will be performed at an additional charge (CPT code(s): 86593).

Limitations

False-positive results have been associated in patients with infections, pregnancy, autoimmune disease, old age, Gaucher disease, and malignancy.

Clinical Significance

This is a non-treponemal screening test for syphilis. False positive results may occur due to systemic lupus erythematosus, leprosy, brucellosis, atypical pneumonia, typhus, yaws, pinta, or pregnancy. Monitoring of RPR is helpful in assessing effectiveness of therapy.

7. HIV 1/2 AG/AB, 4W/RFL

Includes

If HIV Antigen and Antibody, 4th Generation Screen is Repeatedly Reactive, HIV-1/2 Antibody Differentiation will be performed at an additional charge (CPT code(s): 86701, 86702).
If HIV-1/2 Antibody Differentiation is Indeterminate or Negative, HIV-1 RNA, Qualitative, TMA will be performed at an additional charge (CPT code(s): 87535).

Reference Range(s)

HIV Ag/Ab, 4th Generation Non-Reactive

Clinical Significance

This 4th generation HIV Ag/Ab Combo assay is intended to be used as an aid in the diagnosis of HIV1/HIV2 infection, including acute or primary HIV-1 infection.

Alternative Name(s)

Fourth Generation HIV,4th Generation HIV

8. HIV I RNA, QL, TMA

Methodology

Transcription-Mediated Amplification (TMA)

Reference Range(s)

HIV-1 RNA, QN, TMA Not detected

This test was performed using the APTIMA® HIV-RNA Qualitative Assay (Gen-Probe).

Clinical Significance

The APTIMA® HIV-1 RNA, Qualitative assay may be used:
1. As an aid in the diagnosis of acute and primary HIV-1 infection.
2. To confirm HIV-1 infection in persons who repeatedly test positive for HIV-1 infection.
3. To resolve indeterminate or inconclusive HIV-1 Western blot results.

9. Urinalysis

Includes

Macroscopic and Microscopic Examinations

Methodology

Reagent Impregnated Strips/Tablets/Microscopic Examination

Clinical Significance

Dipstick urinalysis is important in accessing the chemical constituents in the urine and the relationship to various disease states. Microscopic examination helps to detect the presence of cells and other formed elements.


CHLAMYDIA/GC RNA, TMA
Hep A AB, Total
Hep B CORE AB Total
Hep C AB
HSV 1/2 IGG HERPSELECT W REF
SYPHILIS
HIV 1/2 AG/AB, 4W/RFL
HIV I RNA, QL, TMA
Urinalisis
Save this product for later

Dedicated. Determined. Dependable. That's our commitment to you.

Always FAIR in our pricing.

Always deliver QUALITY service.

Thank you for being a part of the movement to lower the costs of healthcare. Healthcare news and lab testing news available on our blog. Also learn about symptoms and medications you take that require testing.

1-888-845-2283

1--888-84-LAB-TEST

Use link above to contact us via email. 

 

6175 Hickory Flat Hwy.
Suite 110 #411

Canton, GA 30115

United States

Contact us for International Lab Testing

  • Facebook
  • Instagram

© 2019 by FairPrice Labs. Proudly creating healthcare solutions.